股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 2. ...

Core Points - Ted Pharmaceuticals (03880.HK) announced the resignation of Li Zhongcheng as co-secretary, authorized representative, and legal process agent effective September 26, 2025 [1] - Wu Dongcheng has been appointed as the new co-secretary, authorized representative, and legal process agent effective September 26, 2025, following Li Zhongcheng's resignation [1] - Li Lingmei will continue to serve as the other co-secretary [1]

Core Viewpoint - Ted Medical (03880) announced the resignation of Mr. Li Zhongcheng from multiple positions effective September 26, 2025 [1] Group 1 - Mr. Li Zhongcheng will resign as (i) Co-Company Secretary; (ii) Authorized Representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) Representative for receiving legal documents and notifications in Hong Kong as per Listing Rule Section 19A.13(2) and the Companies Ordinance Chapter 622 [1] - Mr. Wu Dongcheng has been appointed as Co-Company Secretary, Authorized Representative, and Legal Process Agent effective September 26, 2025 [1] - Ms. Li Lingmei will continue to serve as another Co-Company Secretary [1]

Core Points - Mr. Li Zhongcheng has submitted his resignation as (i) Co-Company Secretary; (ii) Authorized Representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) Representative for receiving legal documents and notifications in Hong Kong, effective from September 26, 2025 [1] - Mr. Wu Dongcheng has been appointed as Co-Company Secretary, Authorized Representative, and Legal Process Agent, effective from September 26, 2025 [1] - Ms. Li Lingmei will continue to serve as another Co-Company Secretary [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Medtide Inc. 泰 德 醫 藥（ 浙 江 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 及 豁免嚴格遵守上市規則第3.28條及第8.17條 泰德醫藥（浙江）股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，李忠成先生（「李先生」）已提出辭任(i)本公司聯席公司秘書（「聯席公司秘 書」）；(ii)香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 3.05條項下之授權代表（「授權代表」）；及(iii)根據上市規則第19A.13(2)條及香港 法例第622章公司條例第16部所規定代表本公司於香港接收法律程序文件及通知 之代表（「法律程序代理人」），自2025年9月26日起生效。 李先生確認彼與董事會並無意見分歧，亦無有關彼辭任之事宜須提請本公司股東 或聯交所垂注。 董事會進一步宣佈，李先生辭任後，吳東澄先生（「吳先生」）已獲委任為聯席公司 ...

Financial Performance - Revenue for the first half of 2025 reached RMB 253.8 million, a 28.5% increase from RMB 197.5 million in the same period of 2024[6]. - Gross profit increased by 44.3% to RMB 155.0 million, compared to RMB 107.4 million in the previous year, resulting in a gross margin of 61.1%[6][15]. - Net profit surged by 101.7% to RMB 102.0 million, up from RMB 50.6 million in the prior year, with a net profit margin of 40.2%[6][15]. - Adjusted net profit (non-IFRS measure) increased by 14.9% to RMB 104.1 million from RMB 90.6 million in the previous year[15]. - For the six months ended June 30, 2025, the profit reached RMB 102.0 million, compared to RMB 50.6 million for the same period in 2024, representing a significant increase due to higher gross profit and fair value gains on financial liabilities[47]. - The adjusted net profit for the six months ended June 30, 2025, was RMB 104.1 million, up from RMB 90.6 million in the same period of 2024, reflecting a growth of approximately 15%[48]. - Basic earnings per share for the period was RMB 0.82, compared to RMB 0.40 in 2024, reflecting a 105% increase[96]. - The company reported a total comprehensive income of RMB 101,512,000 for the six months ended June 30, 2025, compared to RMB 50,967,000 in 2024[97]. Operational Highlights - The number of ongoing projects at the end of June 2025 was 1,463, an increase from 1,378 in June 2024[9][11]. - The number of new projects acquired during the first half of 2025 was 4,674, compared to 4,353 in the same period of 2024[9]. - The company expanded its workforce to 520 full-time employees, a 14.5% increase compared to the previous year[7]. - The company has a peptide API production capacity exceeding 500 kg annually, with each batch capable of producing over 30 kg, and can handle multiple orders of 100 kg scale[26]. - The company has 338 ongoing CDMO projects, including nine NCE GLP-1 molecule development projects with seven clients[29]. - The company has passed 17 regulatory and customer audits during the reporting period, demonstrating strong compliance and quality assurance[23]. Market and Industry Insights - The global peptide drug market is projected to grow from $89.5 billion in 2023 to $261.2 billion by 2032, with a compound annual growth rate (CAGR) of 12.6%[28]. - The GLP-1 drug market is expected to grow from $38.9 billion in 2023 to $129.9 billion by 2032, with a CAGR of 14.3%[28]. - The company plans to further develop in the global Tides drug market, particularly in the GLP-1 peptide segment[7]. Financial Position - As of June 30, 2025, the company had cash and cash equivalents of RMB 998.4 million, a substantial increase from RMB 387.2 million as of December 31, 2024, primarily due to operating cash flow and proceeds from a global offering[50]. - The total outstanding borrowings amounted to RMB 50.0 million as of June 30, 2025, with an interest rate ranging from 2.60% to 2.70%[55]. - The company's debt-to-asset ratio improved to 17.1% as of June 30, 2025, down from 72.8% as of December 31, 2024, mainly due to changes in equity and proceeds from the global offering[55]. - The company’s total equity increased to RMB 1,468,903,000 as of June 30, 2025, compared to RMB 318,750,000 at the end of 2024[100]. - The company’s current liabilities totaled RMB 265,349,000 as of June 30, 2025, compared to RMB 172,043,000 at the end of 2024, indicating increased operational activity[99]. Employee and Governance - The company has implemented a high-standard quality management system, with 100 employees in the quality assurance and control department as of June 30, 2025[22]. - The total employee count is 520, with 47% in production, 19% in quality assurance, and 12% in R&D[63]. - The company has adopted a share incentive plan to attract and retain quality employees[63]. - The company maintains a commitment to high standards of corporate governance and has complied with all applicable code provisions since its listing[68]. Future Plans and Investments - The company plans to expand production capacity in the U.S. and China, aiming for an annual capacity of 300 kg in the U.S. and an additional 500 kg in China by the end of 2025[30]. - The company plans to allocate HKD 327.58 million (76.40%) of the net proceeds for expanding service capacity and production through facility construction by December 31, 2026[76]. - The company is preparing for the commercialization of new drugs following regulatory approvals[174]. - The company has plans for market expansion and potential mergers and acquisitions in the future[174]. Regulatory and Compliance - The company received ISO 22716:2007 certification for good manufacturing practices in January 2025[7]. - The independent review report confirms that the interim financial data is prepared in accordance with International Accounting Standard 34[94]. - The company has not identified any matters that would lead to a belief that the interim financial data is not prepared in accordance with the relevant standards[94].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 RMB | | 73,598,888 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

Core Insights - The company reported a 28.5% increase in revenue to RMB 253.8 million for the six months ending June 30, 2025, with a net profit increase of 101.7% to RMB 102.0 million [1] - The gross profit margin improved to 61.1%, up 6.7 percentage points from 54.4% in the previous year, primarily due to lower growth in sales costs compared to reductions in employee compensation and utility expenses [1] Financial Performance - Revenue increased by 28.5% to RMB 253.8 million [1] - Gross profit rose by 44.3% to RMB 155.0 million [1] - Net profit surged by 101.7% to RMB 102.0 million [1] - Gross margin improved to 61.1% from 54.4% [1] Market Presence - The company has established stable customer relationships in over 50 countries, including major markets such as China, the USA, Japan, Europe, South Korea, and Australia [1] - The company provides peptide drug development, production, and CMC filing support services compliant with global regulatory standards [1] Project Pipeline - The number of ongoing CDMO projects increased from 332 to 338 within a year [1] - The company has a strategic focus on GLP-1 pipeline projects, with 338 ongoing CDMO projects, including nine NCE GLP-1 molecule development projects with seven clients [1] Production Capacity - The company has significant peptide API production capacity, with a cGMP-compliant facility in Hangzhou covering over 20,000 square meters [2] - The annual production capacity for peptide APIs exceeds 500 kg, with batch capacities over 30 kg [2] - The company has initiated expansion projects in Rocklin, California, and Hangzhou, including the installation of 3,000-liter SPPS reactors [2]

Core Insights - The company, 泰德医药 (03880), reported a revenue of 254 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 28.52% [1] - Shareholder profit attributable to the company was 102 million RMB, which is a significant year-on-year increase of 101.71% [1] - Basic earnings per share were reported at 0.82 RMB [1] - The increase in revenue is primarily attributed to the growth in FFS and FTE business segments, driven by increased demand for the company's services [1]